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Proinﬂammatory mediators are important in the pathogenesis of IBD, which are regulated by activation of NF-κB. The aim of this
study was to investigate whether melatonin reduces inﬂammatory injury and inhibits proinﬂammatory molecule and NF-κBi n
rats with colitis. Rat colitis model was established by TNBS enema. NF-κB p65, TNF-α,I C A M - 1 ,a n dI κBα in colon tissue were
examined by immunohistochemistry, EMSA, RT-PCR, and Western blot analysis. Expression of proinﬂammatory molecule and
activation of NF-κB were upregulated and IκB level decreased in rats with colitis. Melatonin reduces colonic inﬂammatory injury
through downregulating proinﬂammatory molecule mediated by NF-κB inhibition and blockade of IκBα degradation.
INTRODUCTION
Ulcerative colitis (UC), a major inﬂammatory bowel
disease(IBD),isachronicintestinalinﬂammatorydisease
which aﬄicts more and more people in China [1]. Al-
though exact etiology and pathogenesis remain obscure,
there is substantial evidence that proinﬂammatory cy-
tokines and adhesion molecules including tumor necro-
sis factor-α (TNF-α) and intercellular adhesion molecule-
1 (ICAM-1) exhibit a key role in the inﬂammatory pro-
cess [2, 3, 4]. And many studies have shown increased
production of TNF-α and ICAM-1 in intertinal mucosa,
serum, lamina propria mononuclear cells (LPMC), and
peripheral blood mononuclear cells (PBMC) in patients
with UC, which is thought to be an important factor
in the pathophysiology of intestinal inﬂammation in UC
[5, 6, 7]. At present, medical treatment of UC relies
mainly on traditional drugs: aminosalicylates, corticos-
teroids, and immunosuppressants. These drugs including
glucocorticoids and aminosalicylates reduce inﬂamma-
tory injury and attenuate the expression of some proin-
ﬂammatory molecules but their side eﬀects and systemic
action are so hard that they disturb the life quality of pa-
tients severely, particularly during long-term treatment.
And so, it is very important to ﬁnd an optimal therapy for
UC.
Recent studies have unequivocally shown that the ex-
pressions of TNF-α and ICAM-1 are regulated by the
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transcription factor nuclear factor kappa B(NF-κB); NF-
κB play a central role in immune and inﬂammatory re-
sponses and may be a good target for therapy [8, 9]. NF-
κB is mostly composed of RelA (p65) and NF-κB1(p50);
these NF-κB dimers are kept in an inactive cytoplas-
mic complex by inhibitory proteins, the inhibitor pro-
tein kappa B(IκB) family, in resting cells. NF-κBc a nb e
activated within minutes by a variety of stimuli, includ-
ing inﬂammatory molecules such as TNF-α and IL-1,
growth factors, bacterial lipopolysaccharide (LPS), and
oxidative stress, which induce site-speciﬁc phosphory-
lation of IκB and consecutive rapid dissociation of the
complex accompanied by proteolytic degradation of IκB.
The released NF-κB proteins subsequently transmigrate
from cytoplasm into the nucleus where they can induce
gene transcription by binding to speciﬁc promoter ele-
ments [10, 11, 12]. Activated NF-κBh a sb e e nd e m o n -
strated in colonic epithelial cells and macrophages of pa-
tients with IBD [13, 14], and also NF-κB p65 antisense
oligonucleotide treatment was reported to have much
beneﬁt in experimental colitis, although toxicity eﬀects
must be carefully analyzed [15, 16]. The above data pre-
dict that NF-κB is a new and more eﬀective therapy tar-
get.
Melatonin, mainly produced in the pineal gland,
play an important physiological role in immunoregula-
tion, inﬂammatory responses, and oxidative stress. Gas-
trointestinal tract is a rich source of extrapineal mela-
tonin. And melatonin release may have a direct eﬀect
on many gastrointestinal tissues but may also well in-
ﬂuence the digestive tract indirectly [17]. Some previ-
ous data have shown that melatonin can alleviate colonic
injury in experimental colitis induced by both dextran
sulfate sodium and dinitrobenzene sulfonic acid in rats186 Jun-Hua Li et al 2005:4 (2005)
[18, 19], but the mechanism of action of exogenous
melatonin against inﬂammatory injury is not apparent.
These therapeutic eﬀects of melatonin rely at least par-
tially on immunomodulatory function, for example, in-
hibiting the action of macrophages in inﬂammatory tis-
sues [20]. Meanwhile, other studies have demonstrated
that melatonin exerts an antioxidant and scavenger ef-
fect on free radicals to reduce the severity of colitis
[18].
In this study we investigated if melatonin re-
ducesinﬂammationin2,4,6-trinitrobenzene sulfonicacid
(TNBS)-induced colitis through an inhibitory eﬀect on
proinﬂammatory molecule expression and the transcrip-
tion factor NF-κB.
MATERIALS AND METHODS
Animals
HealthyadultSprague-Dawlay(SD)ratsof bothsexes,
weighing 250 ± 30g, were obtained from the Experimen-
tal Animal Center of Wuhan University (Wuhan, China).
Animals were housed under speciﬁc pathogen-free con-
ditions and allowed access to standard rat chow and wa-
ter. Before the experiments, they were acclimatized to the
surroundings for one week. The study protocol was in ac-
cordance with the guidelines for animal research and was
approved by the Ethical and Research Committee of the
hospital.
Experimentalprotocolandcolitisinduction
Rat model of colitis induced with 2,4,6-trinitro-
benzene sulfonic acid (TNBS, Sigma Co, Shanghai,
China) enema was described in the literature [21]. The
experimental animals were randomly divided into six
groups of 10 each: normal group, model group, 5-
aminosalicylic acid(5-ASA) group, and melatonin treat-
ment group that were treated with saline, TNBS/40%
ethanol(150mg/kg), 5-aminosalicylic acid(100mg/kg),
and melatonin (Sigma Co) at doses of 2.5, 5.0, 10.0mg/kg
enema, respectively (once a day, from the 24hours after
colitis was established to the end of experiment). At the
end of a 4-week period, the animals were sacriﬁced and
the colon samples were collected.
Colon tissues were ﬁxed in 4% paraformaldehyde, de-
hydrated, and paraﬃn embedded. Four-micrometer sec-
tions were cut transversely and stained with hemotoxylin
and eosin. Colon macroscopic and histological damage
indices were evaluated by an independent pathologist
blindly as reported previously [20, 22]. At the same time,
colon samples from the same sites were also obtained and
frozen immediately in liquid nitrogen for subsequent de-
termination.
Immunohistochemistrydetection
Sections of colon tissues were kept in an oven at
4◦C overnight and were deparaﬃnized in xylene and
rehydrated. Endogenous peroxidase activity was blocked
with 1% hydrogen peroxide for 20minutes. And mi-
crowave oven-based antigen retrieval was performed.
Slides were probed with either anti-RelA (1:50, rat mono-
clonal,SantaCruzBiotechnology),anti-TNF-α(1:100,rat
polyclonal, Santa Cruz Biotechnology), or anti-ICAM-1
(1:100, rat monoclonal, Santa Cruz Biotechnology). Sec-
tions were washed three times with PBS for 10minutes
each and incubated with biotin-labeled antirat IgG for
1hour at room temperature, respectively. After three
washes with PBS for 10minutes each, the slides were de-
veloped in 0.05% freshly prepared diaminobenzedine so-
lution for several minutes and then counterstained with
hematoxylin. Incubation with PBS instead of the primary
antibody served as a negative control. In specimens con-
taining positive cells, the positive cells were counted in
ten randomly selected ﬁelds under high-power micro-
scope (400-fold magniﬁcation) for each sample, and the
average was expressed as the density of positive cells.
EMSAanalysis
Nuclear protein extracts were prepared as described
previously [13]. Fresh colon samples were homogenized
in 400µL of hypotonic lysis buﬀer A (10mmol/L HEPES
pH 7.9, 10mmol/L KCl, 0.1mmol/L EDTA, 0.1mmol/L
EGTA, 1mmol/L DTT, and 1mmol/L PMSF). Homog-
enized tissues were incubated on ice for 5minutes, NP-
40 was added to a ﬁnal concentration of 5g/L, and sam-
ples were vigorously mixed and centrifuged. The cy-
toplasmic proteins were removed and the pellet nuclei
were resuspended in 50µLb u ﬀer C (20mmol/L HEPES
pH 7.9, 0.4mol/L NaCl, 1mmol/L EDTA, 1mmol/L
EGTA, 1mmol/L DTT, and 1mmol/L PMSF). After
30-minute agitation at 4◦C, the samples were cen-
trifuged and supernatants, containing nuclear proteins,
were transferred to a fresh vial. The protein concen-
trations of nuclear extracts were determined by Brad-
ford protein assay. Nuclear protein extracts of colon tis-
sues were analyzed by EMSA for NF-κB nuclear translo-
cation as previously described [23, 24]. EMSA binding
reaction mixture contained 8µgp r o t e i no fn u c l e a re x -
tracts, 2µg of poly (deoxyinosinic-deoxycytidylic acid)
(Sigma Co), and [32P]-labeled double-stranded oligonu-
cleotide containing the binding motif of NF-κBp r o b e
(4000cpm) in binding buﬀer (10mmol/L HEPES pH
7.9, 50mmol/L NaCl, 1mmol/L EDTA, 1mmol/L DTT,
100mL/L glycerol, and 0.2g/L albumin). The sequence
of the double-stranded oligomer used for EMSA was 5 -
AGTTGAGGGGACTTTCCCAGGC-3 . The reaction was
incubatedfor30minutesatroomtemperaturebeforesep-
aration on a 50g/L acrylamide gel, followed by autora-
diography. For supershift experiments, 2µgo fr a tm o n -
oclonal antibodies against the p65 subunit (Santa Cruz
Biotechnology) of NF-κB was incubated with the nu-
clear extracts 10 minutes before the addition of the [32P]-
labeled probe and then analyzed as described.2005:4 (2005) Melatonin Reduces Inﬂammatory Injury in Colitis 187
Westernblotanalysis
Colon samples were snap frozen in liquid nitrogen
at the time of removal and later mechanically homog-
enized (20%w/v) in lysis buﬀer consisting of 20mM
HEPES, pH 7.4, 0.1mM EDTA, 12.5mMMgCl 2, 150mM
NaCl, 0.1% Nonidet P40, 0.2mM phenylmethylsulfonyl
ﬂuoride, 1mM dithiothreitol, and 1µg/mL concentration
of each of pepstatin, leupeptin, and aprotinin. The ho-
mogenates were transferred to Eppendorf tubes, soni-
cated for 10seconds and then centrifuged at 14000rpm
for 10minutes. Protein concentrations of samples were
assessed using the method of Bradford protein assay,
a n da l ls a m p l e sw e r ea d j u s t e dt oa ne q u a lp r o t e i nc o n -
tent before analysis. Samples (20µg of total protein)
were separated on a 12% denaturing polyacrylamide gel.
Separated proteins were transferred to a nitrocellulose
membrane (20V, 90minutes; transfer buﬀer 25mM Tris,
190mM glycine, 20% methanol, 0.5% sodium dode-
cyl sulfate) by an electroblotter (Bio-ram). The mem-
brane was placed into blocking buﬀer (5% nonfat milk
in 20mMTris/HCl, pH7.6, 140mM NaCl, 0.5% Tween
20) for one hour at room temperature. Blocking buﬀer
was decanted and the membrane was incubated with
the primary antibody anti-IκBα (1:500 diluted in block-
ing buﬀer, Sigma Co) on a shaker at 4◦C overnight. Af-
ter being washed (in 20mMTris/HCl, pH7.6, 140mM
NaCl, 0.1% Tween 20), the membrane was incubated
with a peroxidase-conjugated secondary antibody, which
was diluted in 5% nonfat milk in wash buﬀer (one
hour; room temperature; gentle shaking). Being washed,
the membrane was exposed to sensitive ﬁlm several
minutes after incubation in Western blotting luminol
reagent (Cell Signal Corp). The bands were quantiﬁed by
densitometry.
RT-PCR
The mRNA expressions of TNF-α and ICAM-1 were
assessed using RT-PCR standardized by coamplifying
housekeeping gene β-actin, which served as an internal
control. Total RNA from colon tissues was isolated using
trizol reagent (Sigma Co) by the single-step method
and was reversely transcribed into cDNA. The resulting
cDNA was used as a template for subsequent polymerase
chain reaction (PCR). The rat-speciﬁc primers (sense
and antisense primers) for TNF-α,I C A M - 1 ,a n dβ-actin
were 5 -CATGATCCGAGATGTGGAACTGGC-3  and
5 -CTGGCTCAGCCACTCCAGC-3  (TNF-α, 315 bp);
5 -AGGTATCCATCCATCCCACA-3  and 5 -AGTGTC-
TCATTCCCACGGA-3  (ICAM-1388 bp); 5 -ATGGAT-
GACGATATCGCTG-3  and 5 -ATGAGGTAGTCTGTC-
AGGT-3  (β-actin, 568 bp), respectively. Ampliﬁcation
was performed in 30 cycles with initial incubation at
95◦C for 3minutes and ﬁnal extension at 72◦Cf o r
7minutes, each cycle of which consisted of denaturation
for 30seconds at 95◦C, annealing for 45seconds at 55◦C,
and extension for 1minute at 72◦C. PCR products were
separated on 15g/L agarose gels containing 0.5g/L of
ethidium bromide and visualized by UV transillumina-
tion. HPIAS-1000 software analysis system was used to
determine the relative absorbance of mRNA expression.
Myeloperoxidaseassay
Colon samples were weighed and homogenized in a
solution prepared from the assay kit (Nanjing Jiancheng
Bioengineering Co Ltd, China), and homogenates of
5% were obtained and used for MPO assay. MPO
can catalyze the redox reaction of H2O2 and 3,3,5,5-
tetramethylbenzidine and produce yellow-colored com-
pounds through whose absorbance at 460nm MPO ac-
tivity was calculated and expressed as U/g wet tissue. One
unit of MPO activity was deﬁned as the quantity of en-
zyme that degraded 1µmol H2O2 at 37◦C per g wet tissue.
Statisticalanalysis
All statistical analyses were performed with SPSS10.0
statisticalpackagefromMicrosoftWindows.Studentt test
and one-way analysis of variance (ANOVA) were used to
compare continuous variables among groups. Data were
ﬁnally expressed as mean ± standard error of the mean.
P values less than .05 were considered statistically signiﬁ-
cant.
RESULTS
Effectofmelatoninoninﬂammatoryinjuryofcolitis
Pronounced pathological changes of colonic mucosa
similar to that in human IBD were observed in rats with
colitis induced by TNBS enema. Most animals inﬂicted
with TNBS enema had disease limited to the rectum and
rectosigmiod, some had disease extending beyond the sig-
moid or had a total colitis. The mucosa was hyperemic,
edematous, and granular, and some small punctate ul-
cers were visible. There was an inﬂammatory inﬁltrate of
neutrophils, lymphocytes, and macrophages. Eosinophils
and mast cells were also present in increased numbers.
The colon mucosal macroscopic and histological injury
indices, and MPO activity were signiﬁcantly increased in
these experimental animals compared with normal con-
trols. Administration with melatonin enema at diﬀerent
dosages couldeﬀectivelyreducethe severity of mucosa in-
jury and alleviate the colitis symptoms. And the parame-
ter of mucosa injury was signiﬁcantly decreased in a dose-
dependentmanner inratstreatedbymelatonin compared
with that in model control animals (P<. 01, Table 1).
Effectofmelatoninonproinﬂammatory
moleculesandNF-κBRelAproteinproduction
The protein expressions of TNF-α and t ICAM-1 in
colon tissues were signiﬁcantly increased in rats inﬂicted
with TNBS enema compared with those of the normal
controls. The positive cells of TNF-α and ICAM-1 were188 Jun-Hua Li et al 2005:4 (2005)
Table 1.Eﬀectsofmelatoninand5-ASAonthemacroscopicalandhistologicaldamageindicesandMPOactivityinrats(x±sn= 10).
a denotes that P<. 01 versus the model group.
Group Doses

mg.kg
−1
Macroscopic index Histological index MPO activity

U.g
−1
Normal — 0.75 ±0.71a 1.1 ±0.83a 25 ±19a
Model — 6.25 ±1.39 6.24 ±1.04 207 ± 26
5-ASA 100 1.60 ±0.53a 1.35 ±0.47a 126 ±15a
Melatonin 2.5 5.70 ±1.21 5.85 ±0.76 190 ± 20
Melatonin 5.0 3.00 ±0.76a 3.88 ±0.99a 155 ±19a
Melatonin 10.0 1.63 ±0.74a 1.38 ±0.52a 129 ±31a
(a) (b)
Figure 1. Immunohistochemical staining of RelA in colon tissues of (a) model rats and (b) rats with melatonin treatment
(10mg.kg−1). SP×200. RelA protein is mainly expressed in the nucleus and cytoplasmic accumulation of RelA is also detected. RelA
expression decreases dramatically in melatonin group.
with brown-yellow cytoplasma or nuclear membrane and
predominantly located within the mucosa and mucosa
lamina propria; positive staining of RelA was mainly ob-
served in the cytoplasm, and nuclear staining for RelA
was also detected (Figures 1, 2,a n d3). RelA, TNF-α,a n d
ICAM-1 protein expression decreased dose dependently
in rats with melatonin treatment. Eﬀect of 10mg/kg
melatonin was similar to that of 5-aminosalicylic acid
(100mg/kg). And similar results were obtained with NF-
κB protein expression (Table 2).
Effectofmelatoninonproinﬂammatory
moleculesmRNAexpression
RT-PCR analysis revealed increased mRNA levels for
TNF-α and ICAM-1 in colon tissues of the model group;
melatonin could reduce molecule mRNA expression dose
dependently; 5-aminosalicylic acid reduced the expres-
sion of molecule mRNAs, too. These results are in accord
with immunohistochemical analysis of molecule expres-
sion (Figure 4).
EffectofmelatoninonNF-κBactivation
NF-κB-DNA binding activity was analyzed by EMSA
analysis. Increased NF-κB DNA binding activity and
the RelA/NF-κB complexes were detected in model ani-
mals. Supershift analysis with antibodies speciﬁc for RelA
(p65) and a competitive study with a 50-fold excess of
unlabeled oligonucleotide showed that the antibody spe-
ciﬁc for RelA which recognizes RelA/NF-κB heterodimer,
unlabeled oligonucleotide diminished the intensity of
RelA/NF-κB complexes and indicated that complex was
the NF-κB binding-speciﬁc band. And the NF-κB-DNA
binding activity was inhibited dose dependently when an-
imals were treated with melatonin and 5-aminosalicylic
acid; the inhibition eﬀect of melatonin was most obvious
at a concentration of 10mg/kg (Figure 5).
EffectofmelatoninonIκBproteinlevels
Western blot analysis of protein extracts of colon tis-
sues showed that IκBα expression was weak in samples
from rats without treatment, while it was stronger in the
rats with melatonin and 5-aminosalicylic acid treatment.
But there was no signiﬁcant diﬀerence in the extent of
IκBα expression in colon tissues of rats with melatonin
treatment and normal controls (Figure 6).
DISCUSSION
The incidence and prevalence of IBD increase in
China, and medical treatment of theirs is sometimes
unsatisfactory at present. Our studies have demon-
strated that melatonin given by intrarectal administra-
tion reduced rats colitis induced by TNBS and eluci-
dated the molecule mechanism of melatonin inhibitory2005:4 (2005) Melatonin Reduces Inﬂammatory Injury in Colitis 189
Table 2. Eﬀects of melatonin and 5-ASA on protein expression of RelA, TNF-α, and ICAM-1 in colon tissue (x ±sn= 10). a denotes
that P<. 01 versus the model group.
Group Doses

mg.kg
−1
RelA TNF-α ICAM-1
Normal — 9.10 ±0.76a 16.03 ±6.21a 13.41 ±4.91a
Model — 60.73 ±13.41 84.09 ±14.52 77.69 ±8.09
5-ASA 100 15.27 ±7.25a 19.95 ±7.43a 20.35 ±8.62a
Melatonin 2.5 52.24 ±10.86 78.20 ±13.65 71.63 ±10.34
Melatonin 5.0 30.26 ±10.20a 53.40 ±8.79a 47.01 ±8.82a
Melatonin 10.0 16.95 ±6.83a 23.04 ±6.76a 21.50 ±6.95a
(a) (b)
Figure2.ImmunohistochemicalstainingforTNF-αproteinexpressionin(a)themodelgroupand(b)melatoningroup(10mg.kg−1).
SP×200. The number of TNF-α immunoreactive positive cells in melatonin group is signiﬁcantly less than that of model group.
(a) (b)
Figure 3. Immunohistochemical staining for ICAM-1 protein expression. SP×200. Expression of ICAM-1 in (a) the normal group,
(b) melatonin group (10mg.kg−1). The ICAM-1 expression was downregulated markedly in melatonin group.
inﬂammatory responses in TNBS-induced colitis by inhi-
bition of NF-κB activation ﬁrstly.
Ulcerative colitis is characterized by chronic inﬂam-
mation of colon of unknown etiology, and inﬁltration
and persistence of inﬂammatory cells within tissues are
hallmarks of inﬂammation [25, 26, 27, 28]. Both TNF-α
and ICAM-1 have been suggested to be important media-
tors involved in the initiation and perpetuation of intesti-
nal inﬂammation in ulcerative colitis, and the activities of
TNF-α and ICAM-1 are often used as sensitive indicators
for evaluating the colitis severity [29, 30]. We conﬁrmed
that colon tissue obtained from rats with TNBS-induced
colitis exhibited signiﬁcantly more TNF-α and ICAM-1
expressions than normal controls, which supported the
idea that proinﬂammatory molecules participate in the
occurrence and development of ulcerative colitis. At the
same time, we found that melatonin inhibited protein ex-
pression of TNF-α and ICAM-1 dose dependently. In ad-
dition, our results showed that melatonin could attenuate
the colitis symptoms such as rectal bleeding and occult190 Jun-Hua Li et al 2005:4 (2005)
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Figure 4. The mRNA expressions of (a) TNF-α and (b) ICAM-1 were assessed using RT-PCR standardized by coamplifying the
housekeeping gene β-actin. Lanes 1–7: model, normal, melatonin (2.5, 5.0, 10.0mg.kg−1), 5-ASA, marker.
blood and reduce the frequency and severity of mucosa
damage dramatically. These signiﬁcant protective eﬀects
may be partly due to its eﬀect on inhibition of expres-
sion of proinﬂammatory molecule including TNF-α and
ICAM-1.
Inordertoelucidatethemechanismofactionofmela-
tonin on proinﬂammatory molecule, we investigated the
mRNA expression of TNF-α a n dI C A M - 1i nc o l o nt i s -
sues of rats and determined the inﬂuence of melatonin
treatment on proinﬂammatory molecule mRNA produc-
tion. We found that the mRNA expressions were in ac-
cord with the results of immunohistochemistry detec-
tion; RT-PCR analysis revealed increased mRNA levels for
TNF-α and ICAM-1 in colon tissues of the model group.
Similarly, melatonin had a dose-dependent eﬀect in de-
creasing mRNA expression of proinﬂammatory molecule.
This prompted us to investigate the regulation of proin-
ﬂammatory molecule gene transcription in the process
of inﬂammatory responses. The important candidate is
transcription factor NF-κB, which positively regulates the
transcriptionofgenesinvolvedinimmuneandinﬂamma-
tory responses.
Activation of NF-κB may be a pivotal event in proin-
ﬂammatory signal transduction. Moreover, it has been
shown that NF-κB activation is increased in the colonic
mucosa of IBD patients [13, 14]. In most resting cells,
transcriptionfactormembersoftheRel-NF-κBar ebound
to cytoplasmic inhibitory factors IκBs and are released
on activation-induced degradation of their cytoplasmic
inhibitors by the proteasome/ubiquitin complex [31, 32,
33]. NF-κB p65 hetero- or homodimers migrate to the
nucleus and regulate transcriptional activity by binding
to speciﬁc DNA sequences in promoter/enhancer regions
of inﬂammation genes. Genes regulated by NF-κB include
those encoding IL-2, IL-6, IL-8, the IL-2 receptor, the IL-
12 P40 subunit, VCAM-1, ICAM-1, TNF-α, and so forth
[8, 9, 31, 32, 33]. And studies have also shown that the
ICAM-1 and TNF-α gene promoters have binding sites
for NF-κB[ 34]; the heightened activation of NF-κBc o u l d
be a major regulator of proinﬂammatory molecule secre-
tion in IBD. We therefore investigated the eﬀect of mela-
tonin on transcription factor NF-κB and our results have
shown that melatonin inhibited nuclear translocation of
NF-κB and mRNA expression controlled by it in rats with
TNBS-induced colitis. Translocation into the nucleus and
binding to target DNA sequences are important events for
NF-κB to control transcription process, which relies on
phosphorylation of IκB, mediated by IκB kinases (IKK-α,
β), followed by its degradation by the proteasome [8, 11].
We further determine if melatonin interferes with IκB2005:4 (2005) Melatonin Reduces Inﬂammatory Injury in Colitis 191
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Figure 5. Electrophoretic mobility shift assay demonstrating
nuclear translocation and DNA binding of NF-κB. (a) Lanes 1–
6: model, melatonin(2.5, 5.0, 10.0mg.kg−1), 5-ASA, normal. (b)
Lanes 1–4: the model group, lanes 2–3: speciﬁc competitor (us-
ing excess of unlabeled oligonucleotide), lanes 1 and 4: super-
shift (addition of p65 antibodies to the nuclear extracts).
levels by Western bolt experiments. We found that pro-
tein concentration of IκBα in rats treated with melatonin
was higher compared with that in rats without treatment,
which indicated that the inhibitory eﬀect of melatonin on
NF-κB activation was mediated by stabilization of IκBα
levels.WealsofoundthatIκBαproteinlevelswerenotsig-
niﬁcantly diﬀerent in colon tissues from rats with mela-
tonin treatment and normal controls; this suggested that
the eﬀect of melatonin on IκBα was probably mainly due
to blocking its degradation. Taken together, these data
obtained in this study provide evidence that melatonin
downregulates inﬂammatory responses through inhibi-
tion of NF-κB.
12 34 56
I-κBα
(a)
123456
β-actin
(b)
Figure 6. Western blotting showed levels of IκBα in colon tis-
sue of rats. Lanes 1–6: normal, model, melatonin (2.5, 5.0,
10.0mg.kg−1), 5-ASA.
Previous studies have reported that glucocorticoids
and salicylates inhibit the activation of NF-κB/Rel
through IκB pathway; Weber et al [35] identiﬁed that
sulfasalazine as a direct inhibitor of IKK-α and IKK-
β blocks IκB degradation, then suppresses NF-κBa c t i -
vation, which contributes to the antiinﬂammatory and
immunosuppressive eﬀects in IBD. Other investigators
[36] demonstrated that increased IκBα synthesis was
present in glucocorticoid-treated patients with Crohn’s
disease and thus attenuated NF-κB activation. In our
study, melatonin may stabilize IκBα against degrada-
tion, which is probably associated with IκBα phospho-
rylation, so it will be important and interesting to de-
ﬁne in which step melatonin aﬀects IκBd e g r a d a t i o n
process, and this will be a focus of future investigations.
To date, medical treatment of UC is limited to
aminosalicylates, corticosteroids, and immunosuppres-
sants. Although a variety of new therapies have been
tested with variable success, none is ideal [37, 38, 39]. In
our experimental model of colitis, melatonin treatment
reduced colonic lesions and improved colitis symptoms
through suppressing NF-κB activation. In conclusion, be-
causeofitssigniﬁcantantiinﬂammatoryproperties,mela-
tonin could be considered as the novel therapeutic al-
ternative for the treatment of IBD. Further studies are
needed to determine how melatonin combines with the
established drugs such as sulfasalazine and corticosteroids
in clinic.
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